Tagged with Asia

India Clinical trials will be a pivotal part of India’s attempts to scale the global pharmaceutical value chain. Following a series of well-publicised scandals in the early 2010s, the country tightened up its clinical research regulations and saw a significant drop in trial numbers. However, with a revised regulatory landscape, a…

India Over the course of his 40-year career, oncologist Dr Ramakant Deshpande has taken an active role in the evolution of cancer care in India and in 2017 he became the executive chairman of the Asian Cancer Institute, a cancer care centre aimed at delivering quality care while addressing affordability. He…

Asia-Pacific The APAC region —with an approximate ten percent growth in trial numbers between 2017 and 2022— is rapidly becoming the world’s leading market for clinical trials. Karen Chu, CEO of Harvest Integrated Research Organization (HiRO), a CRO that serves Asian, US and European clients, has experienced the boom first hand.…

India Pratima Reddy, GM at Merck Healthcare India reviews the importance of Merck’s Indian affiliate, discusses the recent reforms that have contributed both to improving patient access and to fostering foreign investments and innovation, and explains the representation of Merck’s portfolio in the country, and how the company navigates the local…

China Harvest Integrated Research Organization (HiRO) is a CRO that serves both Asian biotechs looking to do clinical trials outside of the region, and US and European clients wanting to conduct clinical research in Asia. CEO and founder Karen Chu explains the company’s integrated approach and how it aims to maintain…

Asia-Pacific Glen Godresse brings over 25 years of pharmaceutical industry experience to his role as Chief Marketing Officer & Head of Commercial Excellence for Menarini’s Asia-Pacific operations. In an exclusive conversation with PharmaBoardroom, he explains how Menarini Asia-Pacific is breaking the mould by focusing on niche therapeutic areas often disregarded by…

Singapore The latest pharma news from Singapore, including J&J Innovation’s continued investment in Singapore; Evotec’s new Singaporean venture, 65LAB; BeiGene’s cancer drug approval in the country; Novo Nordisk’s acquisition of local biotech KBP Biosciences’ late-stage investigational hypertension drug, and Crown Bioscience/JSR Life Sciences’ new manufacturing facility.   Johnson & Johnson Innovation…

Taiwan As a part of the World Health Organisation’s (WHO) COVID-19 Technology Access Pool (C-TAP), the Medicines Patent Pool has signed a worldwide license with Medigen Vaccine Biologics (MVC) for its COVID-19 vaccine, representing a debut on two fronts. Not only is this the first time a COVID-19 vaccine developed by…

Hong Kong 2018 marked a significant milestone in Hong Kong’s journey towards creating a vibrant biotech market for investors which allows Asian innovation to receive the funding it needs to progress. It was in that year that the Hong Kong Stock Exchange (HKEX) launched the bold and visionary move of allowing clinical-stage…

Vietnam As geopolitical tensions between China and the US increase and pharma industry stakeholders are increasingly looking elsewhere in Asia to diversify their supply chains, Vietnam has emerged as a highly promising investment destination with a great deal of potential still to unlock. While government healthcare approaches have led the country…

Hong Kong Almost a decade on from the establishment of a Phase I clinical trial centre in Hong Kong, the city continues to pursue a stronger positioning within the global clinical research landscape. Strengthened by its experience in conducting COVID-19 vaccine trials, the global trends towards clinical research in Asia and more…

Hong Kong Generative Artificial Intelligence (AI) has grabbed a lot of media attention in recent months following the launch of chatbot ChatGPT, but the pharmaceutical industry has long been trying – and struggling – to better integrate AI into the long and failure-fraught drug discovery process. While AI-enabled drug discovery may not…